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Abstract 
Treatment of Tourette syndrome (TS) can be complicated by changes over time in tic expression, 
severity, and co-occurring disorders. Using the 2014 National Survey of the Diagnosis and Treatment of 
ADHD and Tourette Syndrome, this study provides descriptive estimates of the use of behavioral 
interventions and medication among children living with TS. Parent-reported data on 115 children aged 
5–17 years ever diagnosed with TS were analyzed to provide descriptive, unweighted results. Overall, 
77.4% of children had current or past use of any TS treatment; 59.1% ever used behavioral 
interventions and 56.1% had ever taken TS medication. Children with "moderate” or “severe” versus 
“mild” TS, ≥1 co-occurring disorders, and tics that interfered with functioning were significantly more 
likely to have used one or more TS treatments. Side effects were reported for 84.4% of children who 
took TS medication. Most parents of children with current TS (87.2%) were satisfied with the 
management of their child's TS. However, parents of children with “moderate” or “severe” current TS 
were significantly more dissatisfied compared to parents of children with “mild” TS. Findings from this 
study could be used to inform efforts to support children living with TS and their families. 
Keywords 
Tic Disorders, Neurodevelopmental disorders, Movement disorders, Adolescents, Public health, 
Medication, Behavior therapy 
1. Introduction 
Tourette syndrome (TS) is a tic disorder characterized by at least one vocal and multiple motor tics that 
begin during childhood and persist for more than one year (American Psychiatric Association, 2013). 
Tics are usually first noticed when the child is between the ages of 4 to 6 (Hirschtritt et al., 2015; 
Khalifa and Von Knorring, 2005; Wolicki et al., 2019), and TS is typically diagnosed around 8 years 
(Bitsko et al., 2014). The frequency and intensity of tics often waxes and wanes (American Psychiatric 
Association, 2013), but severity usually increases until the child is between the ages of 10 to 12 years 
(Bloch and Leckman, 2009; Wolicki et al., 2019), and declines in adolescence (Groth et al., 2017). Co-
occurring mental, behavioral, and developmental disorders are common for children with TS, with 80% 
to 90% of children with TS having one or more co-occurring disorders (Bitsko et al., 2014; 
Hirschtritt et al., 2015; Wolicki et al., 2019). The most common ever-diagnosed co-occurring disorders 
are attention-deficit/hyperactivity disorder (ADHD, ranging from 32.6%–62.8%), anxiety disorders 
(36.0%–44.9%), and 42.3%–66.1% with obsessive-compulsive disorder (Hirschtritt et al., 2015; 
O'Hare et al., 2016; Wolicki et al., 2019). These characteristics of TS (i.e., changes in tic expression, 
severity, and impairment from co-occurring disorders over time) pose challenges for the treatment and 
management of TS (Murphy et al., 2013; Pringsheim et al., 2019b). Better understanding of the use of 
TS treatments may inform efforts to support children living with TS and their families. 
The American Academy of Child and Adolescent Psychiatry (Murphy et al., 2013) and American 
Academy of Neurology (Pringsheim et al., 2019b) along with international professional societies from 
Canada (Pringsheim et al., 2012; Steeves et al., 2012) and Europe (Roessner et al., 2011; 
Verdellen et al., 2011) have issued clinical practice guidelines for the treatment of TS and other 
persistent tic disorders. Evidence-based behavioral interventions for TS include psychoeducation on 
tics such as providing individuals, parents, teachers, and peers with factual information about TS 
(Murphy et al., 2013; Nussey et al., 2013; Verdellen et al., 2011), school accommodations 
(Murphy et al., 2013), habit reversal therapy (Murphy et al., 2013; Steeves et al., 2012; Verdellen et al., 
2011), and Comprehensive Behavioral Intervention for Tics (CBIT, Pringsheim et al., 2019a), which is 
structured behavioral therapy for tics. The United States (U.S.) Food and Drug Administration (FDA) has 
approved three medications for the treatment of TS (haloperidol, pimozide, and aripiprazole).1 Off-
label use of other medications not specifically approved by the FDA is common for the treatment of TS 
(Pringsheim et al., 2019a; Pringsheim et al., 2019b; Quezada and Coffman, 2018). 
Most research regarding children with TS includes samples recruited from specialty clinics for TS and 
related disorders. Often, these samples are limited to a single geographic area or region and usually 
include children with more severe symptoms (Bitsko et al., 2014; Knight et al., 2012). The National 
Survey of the Diagnosis and Treatment of ADHD and Tourette Syndrome (NS-DATA) was conducted to 
learn more about the experiences of children and families living with ADHD and/or TS in the U.S. 
(Zablotsky et al., 2019). Although NS-DATA was used for this analysis, the results presented in this 
study are not representative nor generalizable to all children with TS within the U.S. The purpose of 
this study is to provide a descriptive analysis of parent-reported treatment for TS from a geographically 
diverse sample of children ever diagnosed with TS, with the goal of better understanding 
characteristics of the child and family that are related to TS treatment received. 
2. Methods 
NS-DATA is a follow-up survey to the 2011–2012 National Survey of Children's Health (NSCH), a 
nationally representative parent-report survey conducted within the U.S. that examined the physical 
and emotional health of children (Bramlett et al., 2017; Zablotsky et al., 2019). NS-DATA was 
conducted in 2014 by the U.S. Centers for Disease Control and Prevention's National Center for Health 
Statistics (NCHS), with support from the National Center on Birth Defects and Developmental 
Disabilities. Children under 18 years of age whose parent had reported that their child was ever 
diagnosed with ADHD or TS at the time of the 2011–2012 NSCH were eligible for NS-DATA. The 
responding parent or guardian (hereinafter referred to as “parent”) had to report that the child had 
ever been diagnosed with TS or ADHD at the time of NS-DATA. The NS-DATA responding parent did not 
need to be the 2011–2012 NSCH respondent, but had to live in the same household with the child at 
the time of the survey. NS-DATA had a TS module and an ADHD module; parents of children who had 
ever received both diagnoses were invited to complete both modules. Our study examined only data 
from the TS module, which took an average of 32 minutes to complete and included children from 44 
of the 50 U.S. states (Zablotsky et al., 2019).2 In total, interviews were completed by parents of 115 
children ever diagnosed with TS, of which 78 had children who had ever received a TS diagnosis at the 
time of the 2011–2012 NSCH, according to parent report. The remaining 37 children had a parent who 
reported only an ADHD diagnosis on the 2011–2012 NSCH but reported their child had been diagnosed 
with TS when recontacted for NS-DATA (for additional details, see Wolicki et al., 2019). 
Current or past use of specified TS treatments was the main outcome of interest for these analyses. 
We also present TS treatment use and its association with covariates such as current TS status, ever-
diagnosed and current co-occurring disorders, as well as worst and current TS severity. We analyzed 
co-occurring disorders as a group rather than by individual disorder (i.e., presence or absence of any 
co-occurring disorders and mean number of co-occurring disorders). A list of the 15 co-occurring 
disorders included in the summary variable can be found in Table 1. For each co-occurring disorder, 
parents were asked if the child had ever been diagnosed with the specified disorder, and if yes, asked if 
the child currently had that disorder. 
Table 1. Summary variables and NS-DATA verbatim survey questions for analyses related to co-occurring disorders, treatments for Tourette 
syndrome (TS), and adverse side effects related to medication taken for TS 
Content-similar summary 
variables 
NS-DATA verbatim survey questions included in each group 
Ever-Diagnosed or Current Co-
occurring Disorders n = 115 
Has a doctor or other health care provider ever told you that your child had:* 
 
  Attention-deficit/hyperactivity disorder (ADHD) or ADD?  
  Anxiety disorder, such as generalized anxiety disorder, panic disorder, or a phobia?  
  Autism Spectrum Disorder or Pervasive Developmental Disorder?  
  Bipolar disorder?  
  Conduct disorder?  
  Eating disorder, such as anorexia or bulimia?  
  Intellectual disability?  
  Intermittent explosive disorder?  
  Language disorder?  
  Learning disorder?  
  Mood disorder, such as depression, or major depressive disorder?  
  Obsessive-compulsive disorder or OCD?  
  Oppositional defiant disorder or ODD?  
  Post-traumatic stress disorder or PTSD?  
  Substance use disorder? 
Current or Past Use of 
Specified Treatments for TS 
n = 115 
Has your child ever received:* 
 
  Behavior treatment based outside of school for Tourette syndrome?†  
  Comprehensive Behavioral Intervention for Tics (CBIT) or habit reversal therapy for Tourette 
syndrome?†  
  School-based behavioral treatment, support, or accommodation for Tourette syndrome?†  
  Any other treatment for Tourette syndrome?†  
Has your child ever taken medication for Tourette syndrome? 
Side Effects Experienced Due 
to TS Medication n = 64 
Please think about side effects from medications that your child has ever taken for Tourette syndrome, 
even if your child does not currently take them now. Due to Tourette syndrome medication, has your 
child ever experienced: 
 
  Being mentally slowed down or sluggish, for example, thinking slowly or being less attentive?  
   Being physically slowed down or sluggish, such as moving slowly?  
  Body twisting, squirming, or other new body movements, not including tics?  
  Sleep problems or insomnia, such as trouble getting to sleep or staying asleep?  
  Weight gain?  
  Any other side effects? 
All survey questions are verbatim from the 2014 National Survey of the Diagnosis and Treatment of ADHD and Tourette Syndrome (NS-DATA). 
⁎ If the responding parent answered “yes,” a follow-up question asking if their child currently had specified co-occurring disorder or was currently 
receiving specified treatment was also asked. Both the current co-occurring disorders (presence or absence) and current use of treatment for TS 
(presence or absence of use) were also analyzed as a group. 
† These four survey questions about use of behavioral interventions for TS were also grouped together to create a dichotomous (presence or absence of 
use) for current and past use of any specified behavioral interventions as treatment for TS. 
 
Table 1 also presents the specified TS treatments reported on in NS-DATA, four of which were 
behavioral interventions, one of which was medication use. We created dichotomous summary 
variables (presence or absence) for current or past use of TS treatment including any of the four 
behavioral interventions and/or medication for TS and use of any behavioral interventions for TS 
(Table 1). To determine severity of TS, parents were asked to describe their child's current TS, as well 
as when the TS symptoms were at their worst, as “mild,” “moderate,” or “severe.” 
Some questions in NS-DATA were only asked for subgroups of children, which are detailed below. 
Specific questions about medication use for TS (e.g., child's age when first started taking TS medication, 
a list of current types of medication taken for TS, and side effects ever experienced due to TS 
medication, were side effects troublesome enough to stop taking the medication3) were only asked of 
parents who had reported “yes” to their child ever taking medication for TS (n = 64). Parents of 
children who ever took TS medication were asked to report if their child had ever experienced six 
specified adverse side effects (see Table 1 for verbatim survey questions) due to TS medication in 
general (not specific to a type or dosage of medication for TS). We present analyses of the six side 
effects individually as well as the mean number reported per child. Parents of children with current TS 
at the time of NS-DATA (n = 82) were asked about the accessibility of TS treatment and their overall 
level of satisfaction with the treatment and management of their child's TS. Parents who reported that 
their child had past TS (i.e., responded “no” to the survey question “does your child currently have 
TS?”, n = 294) were asked if they believed treatment helped the tics go away or if the tics seemed to go 
away on their own. The responding parent was also asked to report the child's age and health 
insurance status at the time of NS-DATA. Other demographic information about the child and the 
household was imported from the 2011–2012 NSCH. Multiple imputation was used to estimate the 
federal poverty level for participants with missing data used to construct that indicator (less than 10% 
of the sample) from the 2011–2012 NSCH; imputations are calculated by NCHS and provided in the 
dataset (Bramlett et al., 2017). 
Due to small sample size and confidentiality concerns, we collapsed most response options into fewer 
categories for our analysis. Although the sample for NS-DATA was drawn from across the U.S., it cannot 
be assumed to be nationally representative of all children with TS. Therefore, we analyzed this small 
probability sample as a convenience sample. We present an unweighted, descriptive analysis of this 
cross-sectional, structured interview survey including percentages, means, and standard deviations 
(SD), when appropriate. We used Fisher's exact test and t-tests for all statistical comparisons. 
Outcomes with small sample sizes (i.e., fewer than 5) were either collapsed into other categories or are 
not presented to protect confidentiality of the respondent families. Any responses of “don't know” or 
refusal to answer the question were categorized as missing throughout our analysis. All analyses were 
conducted using SAS version 9.4 (RTI International; Cary, NC). 
3. Results 
3.1. Sample characteristics, TS severity, and co-occurring disorders 
As previously reported (Wolicki et al., 2019), most children included in the TS module of NS-DATA were 
male (82.6%), non-Hispanic white (70.4%), and had at least one parent who attended some college or 
more (74.8%). The mean child age at the time of NS-DATA was 13.2 years (SD = 2.9). More than half of 
children (59.7%) were living in households with income greater than 200% of the federal poverty level. 
According to parent report, most children (92.9%) had continuous insurance coverage over the past 
year. Among children with continuous insurance coverage (n = 105), 52.9% had private insurance and 
47.1% had public insurance. When “[TS] symptoms were at their worst,” TS was most often rated by 
parents as “moderate” or “severe” (80.9%) as opposed to “mild” (19.1%). Most children (89.6%) had 
one or more ever-diagnosed co-occurring disorders and 85.2% of children currently had one or more 
co-occurring disorders at the time of NS-DATA. 
3.2. Current or past use of any specified behavioral interventions and medication as 
treatments for TS 
Of the 115 children in the sample, 77.4% had ever received treatment for TS; 37.4% of children had 
current or past use of both behavioral interventions and medication, 21.7% had current or past use of 
only behavioral interventions, and 18.3% had current or past use of only medication (Table 2). More 
than half of the children (59.1%) had ever received one or more behavioral interventions as treatment 
for TS and 35.7% had ever received two or more behavioral interventions for TS (Table 2). More than 
four out of ten children (42.1%) had ever received “school-based behavioral treatment, support, or 
accommodation”; 35.1% had received “behavioral treatment based outside of school”; 17.1% received 
“Comprehensive Behavioral Intervention for Tics (CBIT) or habit reversal therapy.” In response to an 
open-ended question, parents reported that about one in five children (18.6%) had ever received 
another non-pharmacological treatment for TS including psychotherapy, counseling, holistic 
treatments, and dietary changes. Over half, 62.6%, of children had a “formal educational plan” (i.e., 
Individualized Education Program or IEP or a 504 accommodation plan); however, this survey question 
did not specify whether the educational plan was related to TS. A little over half (56.1%) of children 
had ever taken medication for TS (Table 2). The mean age when children started taking medication for 
TS was 8.3 years (SD = 2.9). No significant difference in age at the time of diagnosis was found between 
children who had ever taken medication for TS (mean = 7.6 years, SD = 2.6) and those who had not 
(mean = 7.8 years, SD = 2.9, p = 0.62). 
Table 2. Use of Specified Treatments for Tourette syndrome (TS), n = 115 
Current or Past Use of Any TS Treatment* %† n 
Never Received Treatment for TS 22.6 26 
Received Both Specified Behavioral Interventions and Medication for TS 37.4 43 
Received Only Specified Behavioral Interventions for TS 21.7 25 
Received Only Medication for TS 18.3 21 
Current or Past Use of Specified Behavioral Interventions   
1 or more Behavioral Treatments for TS§ 59.1 68 
2 or more Behavioral Treatments for TS 35.7 41 
Current or Past Use of Behavioral Interventions by Type§   
School-based treatment, support, accommodation¶ 42.1 48 
Behavior treatment based outside of school¶ 35.1 40 
Comprehensive Behavioral Intervention for Tics (CBIT) or habit reversal therapy¶ 17.1 19 
Any other non-pharmacological TS treatment¶⁎⁎ 18.6 21 
Current Use of School Support (IEP or 504 plan)¶¶ 62.6 72 
Current or Past Use of Medication for TS 56.1 64 
Data from the 2014 National Survey of the Diagnosis and Treatment of ADHD and Tourette Syndrome (NS-DATA). 
⁎ Participants were only classified as missing if they were missing answers to all questions used to create this derived variable. 
† All percentages are unweighted and not nationally representative. 
§ The category of “1 or more Behavioral Treatments for TS” includes children in the “2 or more Behavioral Treatments for TS.” 
¶ These values are not mutually exclusive. 
⁎⁎ Any other non-pharmacological TS treatment included psychotherapy, counseling, holistic treatments, and dietary changes. 
†† Survey question was not specific to TS: “Does the child currently have a formal educational plan, such as an Individualized Education Program, also 
called an IEP or a 504 plan?”. 
 
3.3. Side effects due to medication for TS 
Parent-reported side effects due to TS medication were common. Of the children who ever took 
medication as treatment for TS (n = 64), parents reported that 84.4% of children had one or more side 
effects; 50.0% had 3 or more side effects due to their TS medication. Specific side effects included 
“being mentally slowed down or sluggish” (58.1%), “being physically slowed down or sluggish” (48.4%), 
“experiencing sleep problems” (42.0%), “experiencing weight gain” (40.6%), and “experiencing body 
twisting, squirming, or other new body movements not including tics” (27.0%). Approximately four in 
ten children (42.2%) had other side effects, such as headaches, mood and behavioral changes, weight 
loss, seizures, and loss of appetite. The mean number of side effects per child was 2.5 (SD = 1.6). No 
difference was found in the mean number of side effects by worst TS severity (“mild,” mean = 2.6, 
SD = 1.7 vs. “moderate” or “severe,” mean = 2.5, SD = 1.6, p = 0.95). 
Of the children who ever took medication as treatment for TS (n = 64), half (50.0%) had side effects 
that were “troublesome enough to stop taking the [TS] medication,” according to parent report. 
Among children with current TS, who had ever stopped a TS medication due to side effects (n = 26), 
42.3% were currently taking medication for TS at the time of NS-DATA. Children who stopped taking a 
medication due to side effects had significantly more side effects reported by parents, compared to 
children who did not stop taking medication due to side effects (mean = 3.3, SD = 1.3 vs. mean = 1.8, 
SD = 1.6, p < 0.01). 
3.4. Clinical characteristics of children with current or past use of TS treatment 
Shown in Fig. 1, the percent of children with any current or past use of TS treatment (specified 
behavioral interventions and/or use of TS medication) was significantly higher among children with 
“moderate” or “severe” worst TS when compared to children with “mild” worst TS (84.9% vs. 45.5%, 
p < 0.01). Fig. 1 shows the percent of children with current or past use of TS treatment was significantly 
higher among those ever diagnosed with one or more co-occurring disorders compared to children 
without a specified co-occurring disorder (80.6% vs. 50.0%, p = 0.03). Among children with tics that 
interfered with functioning (i.e., their “ability to do things that other children could do”), the percent of 
children with current or past use of TS treatment was significantly higher than children with tics that 
did not interfere with their functioning (87.3% vs. 66.0%, p = 0.01). No significant difference was 
documented in current or past use of TS treatment by children with current or past TS (p = 0.60) or “tic 
noticeability to strangers” (p > 0.99). 
 
Fig. 1. Percent of Children with Tourette Syndrome (TS) Who Had Any Current or Past Use of Behavioral 
Interventions or Medication as Treatment for TS by Clinical Characteristics, by Parent-report, n = 115 
Data from the 2014 National Survey of the Diagnosis and Treatment of ADHD and Tourette Syndrome (NS-
DATA). 
† All percentages are unweighted and not nationally representative. 
* Co-occurring disorders included: Attention-deficit/hyperactivity disorder, anxiety disorder, autism spectrum 
disorder or pervasive developmental disorder, bipolar disorder, conduct disorder, eating disorder, intellectual 
disability, intermittent explosive disorder, language disorder, learning disorder, mood disorder, obsessive-
compulsive disorder, oppositional defiant disorder, post-traumatic stress disorder, substance use disorder. 
 
Examination of the same factors by current or past use of specified TS behavioral interventions or TS 
medication revealed similar patterns of significant differences as those for current or past use of TS 
treatment. Specifically, compared to children with “mild” worst TS, children with “moderate” or 
“severe” worst TS were more likely to have current or past use of behavioral interventions (64.5% vs. 
36.4%, p = 0.03) and current or past use of TS medication (62.0% vs. 31.8%, p = 0.01). Children with tics 
that interfered with functioning (according to parent report) were more likely to have current or past 
use of behavioral interventions for TS (p = 0.06) and medication use (p = 0.02) compared to children 
whose tics did not interfere with functioning. Also, children with current or past use of medication for 
TS had significantly more ever-diagnosed co-occurring disorders than children who never took TS 
medication (mean 4.6 disorders, SD = 3.0, vs. 3.3 disorders, SD = 3.2, p = 0.03). No significant 
differences in the current or past use of behavioral interventions for TS or use of TS medication were 
found by child's sex (male vs. female), age (5–12 years vs. 13–17 years), race/ethnicity (non-Hispanic 
white vs. other), or insurance type (private vs. public insurance). 
3.5. Current use of TS treatment among children with current TS 
Nearly three-quarters (73.9%) of children had current TS at the time of NS-DATA. The mean age of 
children with current TS (13.3 years, SD = 2.8) was similar to those with past TS (13.4 years, SD = 3.0). 
Of children with current TS (n = 82), 63.4% currently had “mild” TS and 36.6% currently had 
“moderate” or “severe” TS. Fig. 2 compares treatment types, co-occurring disorders, and treatment 
access and satisfaction for children with “mild” current TS to “moderate” or “severe” current TS. A 
higher percent of children with “moderate” or “severe” current TS were currently receiving one or 
more behavioral interventions for TS (p < 0.01) and were currently taking medication for TS (p = 0.10) 
than children with “mild” current TS. Regardless of the level of current TS severity, a similar percent of 
children currently had one or more co-occurring disorders (p = 0.74). 
 
Fig. 2. Clinical Characteristics by Current Severity of Tourette Syndrome (TS) Among Children with “Mild” or 
“Moderate” and ”Severe” Current TS, by Parent-report, n = 82 
Data from the 2014 National Survey of the Diagnosis and Treatment of ADHD and Tourette Syndrome (NS-
DATA). 
† All percentages are unweighted and are not nationally representative. 
* Co-occurring disorders included: Attention-deficit/hyperactivity disorder, anxiety disorder, autism spectrum 
disorder or pervasive developmental disorder, bipolar disorder, conduct disorder, eating disorder, intellectual 
disability, intermittent explosive disorder, language disorder, learning disorder, mood disorder, obsessive-
compulsive disorder, oppositional defiant disorder, post-traumatic stress disorder, substance use disorder. 
§ Parent selected “very satisfied” or “somewhat satisfied” regarding the overall treatment and management of 
their child's TS. 
 
Among children with current TS (n = 82), 37.8% were currently receiving one or more behavioral 
interventions for TS; 40.2% were currently taking medication for TS. Among children currently taking 
medication for TS, 12 children were currently taking an antipsychotic medication, including the three 
medications approved by the FDA for the treatment of TS (aripiprazole, haloperidol, or pimozide), as 
well as two medications not approved by the FDA for TS (quetiapine and risperidone). Fewer than half 
of children taking an antipsychotic medication were taking one of the FDA-approved medications for 
TS. Other medications children were currently taking as treatment for their TS at the time of NS-DATA 
include alpha adrenergic receptor agonist agents (clonidine or guanfacine, n = 13); 
anticonvulsants/mood stabilizers/antidepressants5 (n = 9); and central nervous system stimulants 
(n = 7). The medications listed are not mutually exclusive; each child could have been taking multiple 
medications for TS from one or more classes. For the 33 children currently taking medication for TS, a 
parent was responsible for making sure their child took their TS medication for 91.0% of children. 
Parents reported that 87.9% of children (n = 29) currently taking a TS medication did not resist taking 
their TS medication in the past year. 
3.6. Parent level of TS treatment satisfaction among children with current TS 
Overall, most parents of children with current TS (90.2%) reported that in the past 12 months they 
were able to get the TS treatment their child needed. Similarly, approximately seven out of eight 
parents (87.2%) reported being “very satisfied” or “somewhat satisfied” with the overall treatment and 
management of their child's TS. No significant differences were found in satisfaction based on the 
current or past use of TS treatments by type (TS treatment, any specified behavioral interventions for 
TS, or any TS medication, p > 0.99 for all comparisons) or the child's age at the time of NS-DATA (5–12 
years of age vs. 13–17 years, p = 0.49). When compared by current severity, parents of children with 
“mild” current TS were more likely to report being able to access needed TS treatments (p = 0.046) and 
being satisfied (i.e., “very satisfied” or “somewhat satisfied”) with the treatment and management of 
their child's TS (p < 0.01) compared to parents of children with “moderate” or “severe” current TS (also 
in Fig. 2). 
3.7. Parent perceptions for children with past TS 
In exploratory analyses, parents of children with past TS at the time of NS-DATA (n = 29) were almost 
equally divided on their perception of what seemed to help their child's “tics go away.” Fifteen parents 
(53.6%) reported that “treatment helped the tics go away,” 13 parents (46.4%) reported “the tics 
seemed to go away on their own,” and 1 parent answered “don't know.” 
4. Discussion 
This study yielded several findings. First, over three-fourths of children (77.4%) had used at least one 
TS treatment (i.e., specified behavioral interventions and/or medication). Although nearly 1 in 4 
children had not received treatment for TS, providers might simply be following the American Academy 
of Neurology's practice guideline recommendations of “watchful waiting” as an acceptable form of 
treatment for children who are not exhibiting impairment due to tics (Pringsheim et al., 2019b). Over 
60% of children with TS had current formal education plans (e.g., IEP or 504 plan). While NS-DATA did 
not ask parents about whether the educational plan was specifically due to TS, an IEP or 504 plan may 
be another way to address TS impairment (Murphy et al., 2013). Educating teachers, school 
administrators, and peers and classmates about TS has been shown to encourage positive attitudes 
toward people with TS, and may in turn, improve functioning among people with TS (Nussey et al., 
2013; Pringsheim et al., 2019b; Tourette Association of America, 2020). 
Second, as is common for children with TS (Bitsko et al., 2014; Hirschtritt et al., 2015; Wolicki et al., 
2019), a majority of children in the sample had one or more co-occurring disorders and the mean 
number of co-occurring disorders was significantly higher among children who had ever received TS 
treatment compared to children who had never received treatment. A recent survey of parents 
conducted by the Tourette Association of America reported that for 42% of children with TS, dealing 
with co-occurring disorders was the greatest challenge for TS management (Malaty et al., 2019). Other 
research has shown that prioritizing treatment for an impairing co-occurring disorder may indirectly 
improve the child's management of TS as well (Eddy et al., 2011; Roessner et al., 2011). Practice 
guidelines recommend an assessment for common co-occurring disorders when evaluating children for 
TS (Murphy et al., 2013; Pringsheim et al., 2019b) due to the high prevalence of co-occurring disorders, 
which has implications for TS treatment. 
Third, similar to previous studies (Leucht et al., 2013; Pringsheim et al., 2011), we found that side 
effects due to medication for TS were common. Parents in our study reported that among children 
who had ever taken medication for TS, almost 85% had one or more side effects and half had stopped 
taking a TS medication due to troublesome side effects. Discontinuing or changing medication over the 
course of TS is common; reasons for switching medication may be due to loss of benefit, side effects, 
or impairment from co-occurring disorders (Carulla-Roig et al., 2018; Farag et al., 2015). The American 
Academy of Neurology and American Academy of Child and Adolescent Psychiatry practice guidelines 
for tic disorders recommend that providers share information to patients about potential side effects, 
and periodically re-evaluate treatment decisions based on current treatment effectiveness, tic severity, 
and presence of side effects (Murphy et al., 2013; Pringsheim et al., 2019b). 
Fourth, parents of children with current TS reported high levels of access to needed treatment and 
satisfaction with the overall treatment and management of their child's TS. These findings align with 
recent research from the same survey (NS-DATA), and a separate parent survey conducted in 2018 that 
reflects the time from onset to TS diagnosis may be decreasing (Malaty et al., 2019; Wolicki et al., 
2019). Decreases in the time to diagnosis have been associated with improved access to needed 
treatment, support, and services (Council on Children with Disabilities et al., 2006). Furthermore, the 
demographic characteristics of the NS-DATA TS module sample suggest a higher socioeconomic status 
and in general, people with higher socioeconomic status have better health and health outcomes 
(National Research Council and Institute of Medicine, 2009). Parents of children with more severe TS 
(“moderate” or “severe”) were significantly less likely than parents of children with “mild” TS to report 
having access to needed treatments and were less satisfied with the treatment and overall 
management of their child's TS. The reasons for reduced access and lower satisfaction among those 
with more severe TS cannot be determined from these data. Other research suggests the most 
available TS treatments were unsuccessful in treating children with more severe TS and parents were 
unable to access more specialized TS treatment options (Hollis et al., 2016). Currently available 
treatments may not be satisfactory in all cases of severe TS. Overall, a high percentage of parents of 
children with TS reported accessible treatment and satisfaction with care, but access to care may 
remain a problem for some (Hollis et al., 2016). 
This study is not without limitations. The survey is comprised of parent-reported indicators that may be 
subject to recall or social desirability bias. In addition, parent reports reflect their perception of the 
child's experience. The data collected were not validated by medical records or clinical assessment. A 
study of parent-reported indicators for children with autism spectrum disorder found that the parent's 
perception of the child's disorder was associated with the impact of the disorder on the family and not 
necessarily the direct impact of the disorder felt by the child (Zablotsky et al., 2015). Although that 
analysis was specific to children with autism spectrum disorder, similar reporting tendencies are a 
potential limitation in this study. In another study examining children's impairment due to tics, parent-
reported impairment was moderately related with the clinical assessment of impairment (Storch et al., 
2007). The granularity of our findings was limited because we needed to collapse or combine many 
indicators throughout our analysis to ensure participants’ confidentiality due to the small sample size. 
In addition, the medications listed are the parent-reported medications the child was currently taking 
for TS at the time of NS-DATA and might not include medications the child had previously taken for TS 
or co-occurring disorders. By survey design, the TS module of NS-DATA included children with a parent-
reported diagnosis of TS or ADHD at the time of the 2011–2012 NSCH interview. Approximately two-
thirds of this study's analytic sample had received a parent reported TS diagnosis at the time of the 
2011–2012 NSCH and the remaining third reported receiving a diagnosis of TS at the time of NS-DATA. 
Therefore, since most of the children were diagnosed with TS before the 2011–2012 NSCH; these 
estimates may not reflect current diagnostic and treatment practices for TS. Finally, the NS-DATA 
sample was nationally drawn, but the results are unweighted and not nationally representative and 
therefore may not be generalizable (Zablotsky et al., 2019). 
Even with these limitations, this study contributes to the understanding of treatment used among 
children with TS. Given the emerging evidence base and updated practice guidelines around TS 
treatment options, continued research into the accessibility of TS treatments including Comprehensive 
Behavioral Intervention for Tics (CBIT), other behavioral interventions and accommodations, and 
medication may inform where additional training or treatment resources may be needed. Ultimately, 
this paper may serve as a resource to inform the continued monitoring of TS treatment and 
management among many children and their families living in the U.S. 
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1The prescribing information for the medications approved by the U.S. Food and Drug Administration 






2Data from the two modules of NS-DATA are available separately. Data access for the TS module 
requires an agreement with the National Center for Health Statistics’ Research Data Center. 
More information is available at www.cdc.gov/rdc. The NS-DATA survey and data for the ADHD 
module are publicly available at www.cdc.gov/nchs/slaits/ns_data.htm. 
3For this analysis, 10 children had no side effects due to TS medication and due to the survey skip 
pattern, were not eligible for the question, “Were these side effects troublesome enough to 
stop taking the medication?” For comparisons of the number of side effects, children in this 
group (i.e., those who did not have any side effects due to TS medication), originally missing, 
were considered as “no” to the question “were these side effects troublesome enough to stop 
taking the medication?,” since they did not experience any side effects due to TS medication to 
be troublesome. 
4Only the 29 survey participants who indicated “no” to the question, “Does your child currently have 
Tourette syndrome?” were eligible for the subsequent questions. Four survey participants 
indicated they “don't know” and therefore were not eligible. 
5Because of small sample size, these medications were combined into a single group to ensure 
participants’ confidentiality. 
